Nuvalent, Inc.
Market Cap
$7.34B
P/E Ratio
-17.14
EPS
$-5.85
Dividend Yield
0.00%
52-Week Range
$63.55 — $113.02
Volume
457.29K
Avg Volume
563.03K
Beta
1.31
Get alerted when NUVL hits your target price.
Free — enter your email to get started
P/E (TTM)
-17.14
Forward P/E
—
PEG Ratio
0.49
P/S (TTM)
0.00
P/B (TTM)
6.13
P/FCF
-88.54
EV/EBITDA
-50.07x
EV/Sales
—
ROE (TTM)
-0.42%
ROA (TTM)
-0.30%
ROIC
-0.13%
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
0.00%
Debt/Equity
0.00
Current Ratio
15.27
EPS Growth (YoY)
-0.32%
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.30%
EPS Growth (5Y)
-0.98%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-5.55
EPS Est (Next Year)
$-4.26
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$18.26
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $137.44(37.1% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
-101234
Outstanding Shares
73.18M
Float
48.73M
Free Float %
66.58%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2021-07-29
Employees
162
CEO
James R. Porter
Index Membership
—
Website
https://www.nuvalent.com
Nuvalent, Inc. (NUVL) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $7.34B, a P/E ratio of -17.14, NUVL is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NUVL against other stocks using dozens of fundamental and technical filters.
Nuvalent, Inc. (NUVL) has a trailing twelve-month (TTM) P/E ratio of -17.14. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Nuvalent, Inc. (NUVL) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Nuvalent, Inc. (NUVL) has a market capitalization of $7.34 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Nuvalent, Inc. (NUVL) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $137.44 implies 37.1% upside from the current price.